Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Moodys
Baxter
Colorcon
Merck

Last Updated: June 25, 2022

ATIVAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Ativan, and what generic alternatives are available?

Ativan is a drug marketed by Hikma and Bausch and is included in two NDAs.

The generic ingredient in ATIVAN is lorazepam. There are eleven drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the lorazepam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ativan

A generic version of ATIVAN was approved as lorazepam by SANDOZ on April 21st, 1987.

  Try it Free

Drug patent expirations by year for ATIVAN
Drug Prices for ATIVAN

See drug prices for ATIVAN

Drug Sales Revenue Trends for ATIVAN

See drug sales revenues for ATIVAN

Recent Clinical Trials for ATIVAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jayasree BasivireddyPhase 3
University Health Network, TorontoEarly Phase 1
University of California, DavisN/A

See all ATIVAN clinical trials

Pharmacology for ATIVAN
Drug ClassBenzodiazepine
Anatomical Therapeutic Chemical (ATC) Classes for ATIVAN

US Patents and Regulatory Information for ATIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma ATIVAN lorazepam INJECTABLE;INJECTION 018140-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Bausch ATIVAN lorazepam TABLET;ORAL 017794-002 Approved Prior to Jan 1, 1982 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Hikma ATIVAN lorazepam INJECTABLE;INJECTION 018140-002 Approved Prior to Jan 1, 1982 AP RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Bausch ATIVAN lorazepam TABLET;ORAL 017794-001 Approved Prior to Jan 1, 1982 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Bausch ATIVAN lorazepam TABLET;ORAL 017794-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ATIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hikma ATIVAN lorazepam INJECTABLE;INJECTION 018140-001 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
Hikma ATIVAN lorazepam INJECTABLE;INJECTION 018140-002 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ATIVAN

See the table below for patents covering ATIVAN around the world.

Country Patent Number Title Estimated Expiration
Netherlands 7300694 See Plans and Pricing
Ireland 38298 PARENTERAL BENZODIAZEPINE COMPOSITIONS See Plans and Pricing
South Africa 7209004 See Plans and Pricing
Australia 5024072 See Plans and Pricing
United Kingdom 1345510 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Dow
Express Scripts
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.